NGM Biopharmaceuticals NGM

$ 1.54 0.0%

Annual report 2023
added 03-11-2024

NGM Biopharmaceuticals Balance Sheet 2011-2024 | NGM

Annual Balance Sheet NGM Biopharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-147 M	-246 M	-56.9 M	-25.6 M	-45.5 M	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	-	5.38 M	5.08 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	9.97 M	17.7 M	333 M	354 M	-	-	-	-	-
Total Current Liabilities	20.1 M	47.8 M	61.4 M	42.6 M	39.7 M	-	-	-	-	-	-	-	-
Total Liabilities	20.2 M	47.8 M	66.7 M	49 M	49.7 M	59.2 M	370 M	392 M	-	-	-	-	-
Deferred Revenue	-	366 K	17.8 M	-	4.87 M	19 M	21.4 M	19.1 M	-	-	-	-	-
Retained Earnings	-724 M	-582 M	-419 M	-299 M	-196 M	-147 M	-147 M	-133 M	-	-	-	-	-
Total Assets	169 M	307 M	402 M	329 M	380 M	246 M	249 M	277 M	-	-	-	-	-
Cash and Cash Equivalents	55.8 M	73.5 M	153 M	149 M	246 M	59.2 M	27.8 M	-	-	-	-	-	-
Book Value	149 M	260 M	336 M	280 M	331 M	187 M	-121 M	-115 M	-	-	-	-	-
Total Shareholders Equity	149 M	260 M	336 M	280 M	331 M	-108 M	-121 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet NGM Biopharmaceuticals

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	1.38 M	-	4.07 M	5.38 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	22.3 M	28.4 M	37.9 M	47.8 M	50 M	-	48.6 M	66.7 M	61.8 M	49.9 M	46 M	49 M	49 M	49 M	49 M	49.7 M	49.7 M	49.7 M	49.7 M	59.4 M	59.4 M	59.4 M	59.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	107 K	689 K	376 K	366 K	6.97 M	-	5.12 M	17.8 M	12.3 M	4.96 M	-	-	-	-	-	4.87 M	4.87 M	4.87 M	4.87 M	19 M	19 M	19 M	19 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-696 M	-668 M	-629 M	-582 M	-545 M	-	-451 M	-419 M	-392 M	-363 M	-326 M	-299 M	-299 M	-299 M	-299 M	-196 M	-196 M	-196 M	-196 M	-147 M	-147 M	-147 M	-147 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	192 M	221 M	259 M	307 M	336 M	-	360 M	402 M	416 M	423 M	446 M	329 M	329 M	329 M	329 M	380 M	380 M	380 M	380 M	246 M	246 M	246 M	246 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	51.5 M	53.3 M	67.5 M	73.5 M	105 M	64.9 M	111 M	152 M	147 M	99.4 M	148 M	147 M	147 M	147 M	147 M	246 M	246 M	246 M	246 M	56.9 M	56.9 M	56.9 M	56.9 M	25.6 M	-	-	-	47.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	170 M	192 M	221 M	260 M	286 M	-	311 M	336 M	354 M	373 M	400 M	280 M	280 M	280 M	280 M	331 M	331 M	331 M	331 M	187 M	187 M	187 M	187 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	170 M	192 M	221 M	260 M	286 M	292 M	311 M	336 M	354 M	373 M	400 M	280 M	280 M	280 M	280 M	331 M	331 M	331 M	331 M	-108 M	-108 M	-108 M	-108 M	-121 M	-	-	-	-115 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency